Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis

NCT04677179 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT04677179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04677179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Nektar Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 22, 2021
Completion date
August 9, 2022
Enrollment
81 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative